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In their review article entitled “Why 
identification of stroke syndromes is still 
important,” Kumar and Kaplan affirmed 
“Within the broad category of brain 
ischemia, subtypes also vary dramatically 
in cause: from systemic hypoperfusion 
to atherosclerotic large artery disease to 
penetrating artery disease to dissection 
to emboli arising from the heart valves or 
atria, to emboli arising from the aorta to 
paradoxical emboli to occlusion of cerebral 
and dural sinus veins to hypercoagulabil-
ity. These subtypes are as different as 
grapes and watermelons: two substances 
contained within the large category of 
fruits” [1].
There is much truth in this picturesque 
statement since ischemic stroke is far from 
being a single disease. It combines several 
clinical syndromes that are sometimes very 
different, with differing pathophysiology, 
clinical manifestations, neuroradiological 
findings and localization. This complexity 
requires an approach that, despite the limi-
tations of a Linnaean taxonomy approach 
to biological material, over time has led to 
various attempts at classification of cerebral 
ischemia based on clinical and anatomic, 
and now finally on a pathophysiological 
basis. The aim of these efforts is likely tied 
to achieving a classification model that is 
as close as possible to the phenomenologi-
cal reality of ischemic stroke in order to 
improve the diagnostic and therapeutic 
approach to ischemic stroke, a disease in 
which these elements are worthy of an 
implementation of neuroimaging tech-
niques, since the use of systemic and intra-
arterial thrombolysis have only partially 
improved in recent years.
Categorization of subtypes of ischemic 
stroke has undergone considerable study, 
and in the past, classifications have been 
based primarily on risk factor profiles, 
clinical features of the stroke and the find-
ings of brain imaging studies: computed 
tomography or MRI, but clinical and 
brain imaging findings in brain ischemia 
are not often specific for any particular 
subtype of ischemic stroke.
In 1993, Adams et al. developed a 
system for the diagnosis of subtype of 
ischemic stroke that uses components 
of existing diagnostic schemes for the 
“The classification in subtypes 
of ischemic stroke appears 
therefore to have important 
pathogenic, clinical and 
epidemiological implications 
as well as from a diagnostic 
and clinical point of view.”
“Determining the cause of stroke 
does influence choices for 
management and in particular it 
can have repercussions on 
epidemiological, pathogenic and 
therapeutic issues.”
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Trial of Org 10172 in Acute Stroke Treatment 
(TOAST) [2].
The TOAST classification system includes 
five categories: large-artery atherosclerosis, car-
dioembolism, small-artery occlusion (lacune), 
stroke of other determined etiology and stroke 
of undetermined etiology. Diagnoses are based 
on clinical features and on data collected by 
tests such as brain imaging (computed tomog-
raphy/MRI), cardiac imaging (echocardiogra-
phy, among others), duplex imaging of extra-
cranial arteries, arteriography and laboratory 
assessments for a prothrombotic state.
Determining the cause of stroke does influ-
ence choices for management and in particu-
lar it can have repercussions on epidemio-
logical, pathogenic and therapeutic issues. 
Anticoagulation therapeutic choice could rep-
resent a good example of the importance of pre-
cise evaluation of stroke subtypes. The use of 
adjusted-dose warfarin for stroke patients with 
atrial fibrillation who do not have significant 
bleeding risk has been advocated in several 
professional guidelines [3–6], and the benefit 
has been demonstrated in clinical practice. 
However, not all strokes in patients with atrial 
fibrillation are cardioembolic in origin [7–9], and 
some evidence suggests that warfarin may not 
prevent noncardioembolic strokes [10]. It has 
also been shown that anticoagulation in patients 
with small-vessel cerebrovascular disease carries 
a higher risk of intracranial hemorrhage. Thus, 
it appears very important to consider stroke sub-
type carefully to avoid starting anticoagulation 
with antivitamin K drugs.
A recent study by Evans et al. including 
386 acute stroke patients with atrial fibrilla-
tion treated with adjusted-dose warfarin or 
aspirin had rates of recurrent stroke by subtype 
and major and minor bleeding complications 
as main outcome measures [11]. These authors 
showed that the rate of recurrent stroke was 
higher but that of major bleeding was lower 
with aspirin. They also showed that increased 
stroke rate with aspirin was due predominantly 
to cardioembolic recurrence in patients present-
ing initially with cardioembolic stroke. The 
recurrence rate in aspirin-treated patients who 
presented with lacunar stroke and atrial fibrilla-
tion was similar to that seen in patients receiv-
ing warfarin. The findings of this study strongly 
indicate how determination of stroke subtype 
may be important in anticoagulation decisions 
for secondary prevention of stroke.
Stroke subtype may also significantly differ 
due to the epidemiological relationship with dif-
ferent cerebrovascular factors and some patho-
physiological instances such as inflammatory 
activation degree of the acute phase. Precise 
classification of stroke also has epidemiologic 
involvement, and several studies have evaluated 
the role of cardiovascular risk factors and stroke 
subtypes.
Our group conducted a study to evaluate cer-
ebrovascular risk factor prevalence in diabetic 
stroke patients compared with nondiabetics, 
to analyze whether diabetics have a different 
prevalence of stroke subtypes as classified by the 
TOAST classification. We reported that diabe-
tes was associated with lacunar ischemic stroke 
subtype and with a record of hypertension [12].
Our group also conducted a study to evaluate 
immune-inflammatory activation in the acute 
phase of stroke in relation to time of symptom 
onset, diabetic state and diagnostic subtype. 
We reported significantly higher plasma lev-
els of cytokines, selectins, adhesion molecules 
and PAI-1 and diabetic stroke patients exhib-
ited higher plasma levels of PAI-1 compared 
with nondiabetic patients [13]. Lacunar strokes 
exhibited significantly lower levels of TNF-α 
and IL1-β P-selectin and ICAM-1 compared 
with nonlacunar strokes. Moreover, diabetic 
patients with lacunar strokes exhibited a minor 
grade of immune-inflammatory activation of 
the acute phase at 24–72 h and 7–10 days after 
stroke onset. The minor grade of immune- 
inflammatory activation of patients with lacunar 
strokes, particularly diabetics, could be related to 
the minor extension of the infarct size, owing to 
the typical microvascular disease of diabetic sub-
jects which could also explain the better outcome 
of this subtype of ischemic stroke reported.
In another recent study our group showed 
that among patients with acute ischemic stroke, 
patients with cardio-embolic subtype showed 
significantly higher plasma levels of TNF-α, 
IL-6 and IL1-β, whereas lacunar subtype 
showed significantly lower plasma levels of these 
cytokines [14].
Our study further supports the hypothesis 
that inflammation may have an important role 
in the pathogenesis of ischemic strokes, but 
our findings also suggest a peculiar immune-
inflammatory pattern in each subtype of acute 
ischemic stroke. Patients with cardio-embolic 
strokes, compared with other subtypes, showed 
a higher degree of acute neurological deficit 
“...our group showed that 
among patients with acute 
ischemic stroke, patients 
with cardio-embolic 
subtype showed 
significantly higher plasma 
levels of TNF-α, IL-6 and 
IL1-β, whereas lacunar 
subtype showed 
significantly lower plasma 
levels of these cytokines.”
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on admission evaluated by SSS and a higher 
degree of immune-inflammatory activation of 
the acute phase. On the other hand in patients 
with lacunar stroke, compared with other sub-
types, we observed a lower degree of acute neu-
rological deficit on admission evaluated by SSS 
and a lower degree of immune-inflammatory 
activation of the acute phase. Nevertheless, 
patients with large artery atherosclerotic stroke 
(LAAS) subtype showed higher median plasma 
levels of some immune- inflammatory mark-
ers (TNF-α, IL-6 and IL1-β) compared with 
lacunar subtype, but lower median plasma 
levels of these biomarkers compared with the 
cardioembolic-infarct subtype.
Although several intervention trials with 
ACE-inhibitors, angiotensin receptor block-
ers, other antihypertensives or statins have 
been shown, sometimes in primary prevention 
and mostly in a secondary prevention setting, 
a significant reduction of stroke incidence, yet 
few studies, with the exception of some such 
as SPARCL study [15], used a TOAST subtype 
oriented analysis. Therefore it is difficult to 
extrapolate the real benefit of pharmacological 
prevention strategies against atherothrombotic 
subtype that is represented by the LAAS and 
also with regard to lacunar subtype as an expres-
sion of lipohyalinosis process which is a further 
aspect of atherosclerosis. More frequently stroke 
classification in clinical trials concerns prognosis 
with terms such as fatal or nonfatal that are less 
likely to reveal thrombotic or embolic type.
The classification in subtypes of ischemic 
stroke appears therefore to have important 
pathogenic, clinical and epidemiological impli-
cations as well as from a diagnostic and clinical 
point of view. Correctly classifying the TOAST 
subtype in the light of some recent studies also 
leads to a number of epidemiological and clini-
cal considerations that take on a very impor-
tant role in diagnostics and therapeutics. Proper 
assessment of initial stroke subtype in a clinical 
setting allows physicians to optimize second-
ary prevention through the appropriate selec-
tion of drug (anticoagulant or antiplatelet). The 
same approach could relate to the decision to 
use high doses of atorvastatin as indicated by 
the SPARCL study in the secondary preven-
tion of ischemic stroke. Neither the SPARCL 
study nor other studies that have evaluated the 
effectiveness of statins in primary prevention 
of ischemic stroke have in fact opted for an 
assessment of the type that could be oriented 
to identify the subtype likely to show greater 
efficacy of the therapeutic estimate with high-
dose atorvastatin in reducing the recurrence of 
atherosclerotic strokes (LAAS), unlike the other 
two types of ischemic stroke identified by the 
TOAST classification subtype as lacunar and 
cardioembolic that in the light of the epidemio-
logical studies available so far do not seem to 
have a background of athero sclerosis. Ischemic 
stroke is a common multifactorial disease, which 
is affected by a number of genetic mutations 
and environmental factors. In a recent study 
we reported a relationship between pro-inflam-
matory/anti-inflammatory (1/1 IL-1 variable 
number tandem repeat of 86 bp) and throm-
botic-/fibrinolytic-gene single-nucleotide poly-
morphisms (CC TPA genotype) and lacunar 
ischemic stroke that may contribute to delineate 
a possible stroke risk profile in subjects with cer-
ebrovascular risk factors [16]. Future studies will 
be addressed to better tailor preventive strategies 
according to clinical subtypes of stroke to opti-
mize drugs adapted to real thrombotic ischemic 
events. Each ischemic stroke subtype as reported 
by some studies is related to inflammation and 
arterial stiffness in a peculiar way, and to date 
no study has addressed the effects of secondary 
prevention with cardiovascular active drugs on 
these markers in relationship to TOAST sub-
type, so this topic could represent a possible field 
of study [17–20].
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